GlassScriptPhysician profile
Rekha Ranade Kapur
NPI 1568416972
$1,073.62
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $146 · 2021: $330 · 2022: $83.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $171.25 | 2019-2021 | |
| Allergan, INC. | $165.42 | 2019-2020 | |
| Abbvie INC. | $164.55 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $96.22 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $86.61 | 2019-2021 | |
| Eisai INC. | $70.21 | 2021 | |
| Vanda Pharmaceuticals INC. | $37.71 | 2019 | |
| Orexo US, INC. | $37.02 | 2019-2020 | |
| Adlon Therapeutics L.P. | $35.20 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $34.58 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.25 | 2020 | |
| Neuronetics, INC. | $28.13 | 2019 | |
| Bausch Health US, LLC | $25.48 | 2019 | |
| Alkermes, INC. | $22.01 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.45 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $20.33 | 2019 | |
| Jazz Pharmaceuticals INC. | $16.57 | 2019 | |
| Avanir Pharmaceuticals, INC. | $11.63 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rekha Ranade Kapur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.